Geneva, April 28 -- International Clinical Trials Registry received information related to the study (ChiCTR2600122640) titled 'Efficacy and Safety of Different Background Doses of Tegileridine for Patient-Controlled Intravenous Analgesia After Open Surgery for Ovarian Cancer: A Randomized Controlled Trial' on April 16.
Study Type: Interventional study
Study Design:
Parallel
Primary Sponsor: Chongqing University Cancer Hospital
Condition:
Ovarian cancer
Intervention:
Background Group (A Group):Tegeline 6mg + Ondansetron 8mg diluted in normal saline to 0.025mg/ml, total volume 240ml. Background infusion rate set at 3ml/h (0.075mg/h), bolus dose 3ml per press, lockout time 10 minutes
Low Background Group (B Group):Tegeline 6mg + Ond...